MediciNova Achieves Significant Milestones in 2025, Sets Stage for 2026

MediciNova achieved significant milestones in 2025 despite global uncertainty, completing patient enrollment in three clinical trials and launching an Expanded Access Program for ALS. The company is optimistic about advancing its programs, including the OXTOX Study for chemotherapy-induced peripheral neuropathy and the MN-001-NATG-202 Study for hypertriglyceridemia, non-alcoholic fatty liver disease, and Type 2 diabetes. With a strong track record of innovation, MediciNova is poised for a pivotal year in 2026.